Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service kyphoplasty & vertebroplasty cases in Maryland: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 8% on average (184 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 10 | 783 | 14% |
| 2020 | 8 | 684 | 15% |
| 2021 | 5 | 667 |
Vertebral compression fracture augmentation; IR, pain, spine surgeons. Professional codes (what the surgeon bills): CPT 22513, 22514, 22510, 22511.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Maryland; 5 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Decompression & minimally invasive spine | 71 | 2,940−4.2%/yr | −4.2%/yr | 3.31.0× | 5% | 3,010 in 2030+0.4%/yr |
| Lumbar fusion |
Kyphoplasty & vertebroplasty in every state, and its device makers · Every procedure market in Maryland · Every state · Compare with Florida
| ≈ 680 |
| – |
| 2026 est. | ≈ 700 | – |
| 19% |
| 2022 | 7 | 642 | 22% |
| 2023 | 7 | 695 | 25% |
| 2024 | 8 | 809 | 28% |
| 2025 from claims | – | 675 546–793 | 29% |
| 2026 forecast | – | 695 545–873 | 29% |
| 2027 forecast | – | 705 522–931 | 29% |
| 2028 forecast | – | 714 506–986 | 30% |
| 2029 forecast | – | 724 492–1,038 | 31% |
| 2030 forecast | – | 733 480–1,088 | 31% |
In 2025, 43% hospital outpatient, 6% surgery center, 51% office. The share outside the hospital has moved +47 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| 3,866−5.3%/yr |
| −5.3%/yr |
| 1.8 |
| 26% |
| 3,550 in 2030−1.4%/yr |
| Virginia | 21 | 1,869−3.9%/yr | −3.9%/yr | 1.8 | 28% | 2,170 in 2030+2.6%/yr |
| North Carolina | 16 | 1,376−9.2%/yr | −9.2%/yr | 1.4 | 27% | 1,380 in 20300%/yr |
| Georgia | 9 | 1,369−5.8%/yr | −5.8%/yr | 1.6 | 22% | 1,270 in 2030−1.2%/yr |
| Oklahoma | 16 | 1,356−6.7%/yr | −6.7%/yr | 2.8 | 48% | 1,260 in 2030−1.2%/yr |
| Tennessee | 12 | 1,040−6.3%/yr | −6.3%/yr | 1.5 | 60% | 1,070 in 2030+0.5%/yr |
| Alabama | 5 | 752−5.3%/yr | −5.3%/yr | 1.7 | 33% | 680 in 2030−1.7%/yr |
| South Carolina | 7 | 691−9%/yr | −9%/yr | 1.0 | 12% | 870 in 2030+3.9%/yr |
| Arkansas | 11 | 674−8.7%/yr | −8.7%/yr | 1.8 | 37% | 540 in 2030−3.7%/yr |
| Louisiana | 3 | 600−4.7%/yr | −4.7%/yr | 1.4 | 24% | 620 in 2030+0.4%/yr |
| Mississippi | 7 | 578−8.4%/yr | −8.4%/yr | 1.5 | 34% | 660 in 2030+2.3%/yr |
| Kentucky | 5 | 575−12%/yr | −12%/yr | 1.2 | 21% | 690 in 2030+3%/yr |
| Delaware | 2 | 124−1.1%/yr | −1.1%/yr | 0.7 | 32% | 260 in 2030+13%/yr |
| 58 |
| 2,364−2.2%/yr |
| −2.2%/yr |
| 2.60.8× |
| 5% |
| 2,480 in 2030+0.8%/yr |
| Cervical fusion & disc arthroplasty | 34 | 1,470−1.4%/yr | −1.4%/yr | 1.61.0× | 5% | 1,510 in 2030+0.4%/yr |
| SI joint fusion | 2 | 164+22%/yr | +22%/yr | 0.20.5× | 0% | 290 in 2030+10%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Johnson & Johnson MedTech leads with 44% of company spending on these surgeons in 2025, +33 pts on 2024.
In 2025, 4 companies reported engagement with Maryland’s surgeons worth $39K in consulting, speaking, meals and travel tied to these products, about $4,902 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 1 clearance or approval in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.